Skip to main content
. 2021 Feb 8;13(2):261. doi: 10.3390/v13020261

Figure 2.

Figure 2

RSV co-immunoprecipitation by RBD1,2 is inhibited by Palivizumab. Adding increasing concentrations of the anti-RSV-F antibody Palivizumab inhibits this interaction (lanes 1, 2 and 3). Lane 4 is an RSV-only control. RSV-F1 protein is detected using NCL-RSV3 primary antibody and RBD1,2 with D6 anti-nucleolin monoclonal antibody. This experiment was repeated 4 times.